Results 221 to 230 of about 205,631 (301)

Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response. [PDF]

Adv Radiat Oncol
Floberg JM, Kyriakopoulos CE, Cho SY.
europepmc   +1 more source

The PRAGMATIC pathway ‐ PRostate cancer diAGnosis and MAnagement Triage In Clinical care

BJU International, EarlyView.
Objectives To investigate whether nurse navigator‐led triaging of high‐risk patients may reduce prostate cancer (PCa) diagnosis and treatment times using an in‐house bespoke PRostate cancer diAGnosis and MAnagement Triage In the Clinial care pathway (PRAGMATIC) triaging system, as locally advanced/metastatic disease should be diagnosed and treated ...
Abhishek Sharma, Teresa Campbell, Sagar Kanabar, Hannah Soanes, Ganesh Sathanapally, Anthony Bates, Rincy John, Charlotte Adams, Aisling Brassill, Bryony Lennon, Sanjay Sinha, Louise Flaxman, Vanessa von Hasseln, Philip Camilleri, Ami Sabharwal, Philip Charlton, Gerard Andrade, Mark Tuthill, Andrew Protheroe, Alastair D. Lamb, Tom Leslie, Aaron Leiblich, Francisco Lopez, Clare Verrill, Fergus Gleeson, Ruth MacPherson, Freddie C. Hamdy, Richard Bell, Richard J. Bryant   +28 more
wiley   +1 more source

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. [PDF]

PLoS One
Das G, Ptacek J, Campbell J, Li X, Havlinova B, Noonepalle SK, Villagra A, Barinka C, Novakova Z.   +8 more
europepmc   +1 more source

Dosimetry and immunohistochemistry study to establish radiolabelled prostate-specific membrane antigen (PSMA) as a potential theranostic target in high-grade glioma treatment

Benger M, Krokos G, Daga K, Wright A, Bodi I, Marchi F, Jeljeli S, Livieratos L, Rosekilly J, Lavrador J, Kinsella S, Wood T, Marsden P, Gillett C, Blower P, Terry S, Mulholland N, Brazil L, Ashkan K, Cook G, Hammers A, Booth TC.   +21 more
europepmc   +1 more source

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. [PDF]

Eur Urol
Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE.   +26 more
europepmc   +1 more source

Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial

BJU International, EarlyView.
Objectives To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform‐positive and ‐negative prostate cancer (PCa) and the 15‐year risk of metastasis or death from PCa in patients who underwent radical prostatectomy ...
Nikita Sushentsev, Anne Y. Warren, Richard Colling, Clare Verrill, Ekaterina Pazukhina, Oleg Blyuss, Alexey Zaikin, Tyler M. Seibert, Tristan Barrett, Jon Oxley, Ian G. Mills, Richard J. Bryant, J. Athene Lane, Jenny L. Donovan, David E. Neal, Freddie C. Hamdy   +15 more
wiley   +1 more source

Therapeutic Challenges in Metastatic Castration-Resistant Prostate Cancer: A Case Study and Review of Prostate-Specific Membrane Antigen-Targeted Therapy Failures in Highly Prostate-Specific Membrane Antigen-Avid Disease. [PDF]

Cureus
Moghrabi S, Al-Houwari R, Ruzzeh S, Al-Ibraheem A.   +3 more
europepmc   +1 more source

Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro [PDF]

, 2015
Ashkan, Keyoumars, Butt, Arthur M., Fillmore, Helen L., Higgins, Samantha C., Pilkington, Geoffrey J.   +4 more
core   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Novel Combination of Metronomic Cyclophosphamide and Darolutamide Induces Sustained Clinical Response in Heavily Treated Prostate Cancer with Prostate-Specific Membrane Antigen-Negative Liver Metastases and Rapid Disease Progression. [PDF]

Case Rep Oncol
Patel VM, Cai Q, Ahn R, Hill K, Wang J.
europepmc   +1 more source